Baxter International has reported positive Phase III clinical trial results for its investigational haemophilia drug BAX 817. The recombinant factor VIIa …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

